Pro-oxidant antioxidant balance in patients with non-alcoholic fatty liver disease
- PMID: 31191836
- PMCID: PMC6536017
Pro-oxidant antioxidant balance in patients with non-alcoholic fatty liver disease
Abstract
Aim: We aimed to determine these parameters in patients with non-alcoholic fatty liver disease using pro-oxidant antioxidant balance assay.
Background: In human, pro-oxidants and antioxidants are normally produced and there is a balance between production and deletion of them. When the balance between oxidants and antioxidants are disrupted oxidative stress occurs. Oxidative stress is known one of the main mechanisms for the development of nonalcoholic fatty liver disease. Many investigations have evaluated some oxidants and/or antioxidant status in these patients. However, studies explaining the antioxidant status and the oxidant burden in these patients are lacking.
Methods: Sera from 35 healthy subjects and 38 patients with non-alcoholic fatty liver disease were recruited. Then, the pro-oxidant burden and the antioxidants capacity were measured by pro-oxidant antioxidant balance assay.
Results: There was no significant difference in the mean pro-oxidant antioxidant balance values between the two study groups. The results demonstrated that serum pro-oxidant antioxidant balance values were positively correlated with BMI and age in the patient group. Furthermore, the pro-oxidant antioxidant balance significantly increased in women when compared with men in all participants.
Conclusion: It demonstrated that increased antioxidant status could be as a response reflecting of the organism to elevated oxidants in NAFLD patients which may lead to unchanged PAB values.
Keywords: NAFLD; Oxidative stress; Pro-oxidants/ antioxidants balance.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures

Similar articles
-
Association between oxidative stress and liver fibrosis severity in non-alcoholic fatty liver disease: insights from the pro-oxidant antioxidant balance method in a population from Tehran and Mashhad, Iran.Front Med (Lausanne). 2025 Mar 12;12:1539605. doi: 10.3389/fmed.2025.1539605. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40144874 Free PMC article.
-
Oxidative stress and cardiometabolic biomarkers in patients with non-alcoholic fatty liver disease.Sci Rep. 2021 Sep 16;11(1):18455. doi: 10.1038/s41598-021-97686-6. Sci Rep. 2021. PMID: 34531465 Free PMC article.
-
The effect of curcumin with piperine supplementation on pro-oxidant and antioxidant balance in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial.Drug Metab Pers Ther. 2019 May 30;34(2):/j/dmdi.2019.34.issue-2/dmpt-2018-0040/dmpt-2018-0040.xml. doi: 10.1515/dmpt-2018-0040. Drug Metab Pers Ther. 2019. PMID: 31145689 Clinical Trial.
-
The Role of Antioxidants in the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease: A Systematic Review.Antioxidants (Basel). 2024 Jun 29;13(7):797. doi: 10.3390/antiox13070797. Antioxidants (Basel). 2024. PMID: 39061866 Free PMC article. Review.
-
New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress.Nutrients. 2020 Sep 10;12(9):2762. doi: 10.3390/nu12092762. Nutrients. 2020. PMID: 32927776 Free PMC article. Review.
Cited by
-
Measuring the Effects of Berberine on Serum Prooxidant-Antioxidant Balance in Metabolic Syndrome.Methods Mol Biol. 2022;2343:309-318. doi: 10.1007/978-1-0716-1558-4_22. Methods Mol Biol. 2022. PMID: 34473333
-
Association between oxidative stress and liver fibrosis severity in non-alcoholic fatty liver disease: insights from the pro-oxidant antioxidant balance method in a population from Tehran and Mashhad, Iran.Front Med (Lausanne). 2025 Mar 12;12:1539605. doi: 10.3389/fmed.2025.1539605. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40144874 Free PMC article.
-
The effect of DASH diet on atherogenic indices, pro-oxidant-antioxidant balance, and liver steatosis in obese adults with non-alcoholic fatty liver disease: A double-blind controlled randomized clinical trial.Health Promot Perspect. 2023 Apr 30;13(1):77-87. doi: 10.34172/hpp.2023.10. eCollection 2023. Health Promot Perspect. 2023. PMID: 37309438 Free PMC article.
References
-
- Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14:32–42. - PubMed
-
- Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Molecular Med. 2009;87:679. - PubMed
-
- Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quinones L, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci. 2004;106:261–8. - PubMed
-
- Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir E, et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2005;100:850–5. - PubMed
LinkOut - more resources
Full Text Sources